Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI)

Hospital de Clinicas de Porto Alegre70 enrolled

Overview

The purpose of this study is to evaluate the effects of intravenous insulin/24 hours to normalize glycemia upon markers of oxidative stress (protein oxidation and total antioxidant defense) and inflammation (C-reactive protein (CRP) and sCD40L) in diabetic patients submitted to PCI with stent.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus Percutaneous Coronary Intervention

Interventions

Intravenous InsulinDRUG

continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Diabetes Mellitus submitted to Percutaneous Coronary Intervention with Stent bare metal * Age: 18-80 years old Exclusion Criteria: * Restenosis * Drug elution stent * Acute coronary syndrome at last 30 days * Use anti inflammatory, antibiotic, vitamin E * Inflammatory disease or oncologic

Outcomes

Primary Outcomes

Reintervention, Myocardial Infarction, Cardiovascular Death

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.